Compare BKU & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | EVO |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 934.1M |
| IPO Year | 2010 | N/A |
| Metric | BKU | EVO |
|---|---|---|
| Price | $45.14 | $2.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $51.58 | $7.00 |
| AVG Volume (30 Days) | ★ 729.1K | 93.6K |
| Earning Date | 04-22-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 14.61 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $21,732,000.00 | N/A |
| Revenue This Year | $16.26 | $1.37 |
| Revenue Next Year | $4.78 | $10.05 |
| P/E Ratio | $54.94 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $33.06 | $2.31 |
| 52 Week High | $52.11 | $4.80 |
| Indicator | BKU | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 40.58 |
| Support Level | $44.10 | $2.32 |
| Resistance Level | $45.65 | $3.78 |
| Average True Range (ATR) | 1.09 | 0.09 |
| MACD | -0.23 | -0.06 |
| Stochastic Oscillator | 7.07 | 17.66 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.